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Abstract
Background: A proportion of individuals who start antiretroviral therapy (ART) fail to achieve
adequate CD4 cell reconstitution despite sustained viral suppression. We determined the
frequency and clinical significance of suboptimal CD4 reconstitution despite viral suppression (SO-
CD4) in an urban HIV research cohort in Kampala, Uganda
Methods: We analyzed data from a prospective research cohort of 559 patients initiating ART
between 04/04–04/05. We described the patterns of SO-CD4 both in terms of:- I) magnitude of
CD4 cell increase (a CD4 count increase < 50 CD4 cells/μl at 6 months, <100 cells/μl at 12 months;
and <200 cells/μl at 24 months of ART) and II) failure to achieve a CD4 cell count above 200 cells/
μl at 6,12 and 24 months of ART. Using criteria I) we used logistic regression to determine the
predictors of SO-CD4. We compared the cumulative risk of clinical events (death and/or recurrent
or new AIDS-defining illnesses) among patients with and without SO-CD4.
Results: Of 559 patients initiating ART, 386 (69%) were female. Median (IQR) age and baseline
CD4 counts were 38 yrs (33–44) and 98 cells/μl (21–163) respectively; 414 (74%) started a d4T-
based regimen (D4T+3TC+NVP) and 145 (26%) a ZDV-based regimen (ZDV+3TC+EFV). After 6,
12 and 24 months of ART, 380 (68%), 339 (61%) and 309 (55%) had attained and sustained HIV-
RNA viral suppression. Of these, 78 (21%), 151 (45%) and 166 (54%) respectively had SO-CD4
based on criteria I), and 165(43%), 143(42%) and 58(19%) respectively based on criteria II). With
both criteria combined, 56 (15%) and 129 (38%) had SO-CD4 at 6 and 12 months respectively. A
high proportion (82% and 58%) of those that had SO-CD4 at 6 months (using criteria I) maintained
SO-CD4 at 12 and 24 months respectively. There were no statistically significant differences in the
incidence of clinical events among patients with [19/100PYO (12–29)] and without SO-CD4 [23/
100PYO (19–28)].
Conclusion: Using criteria I), the frequency of SO-CD4 was 21% at 6 months. Majority of patients
with SO-CD4 at 6 months maintained SO-CD4 up to 2 years. We recommend studies of CD4 T-
cell functional recovery among patients with SO-CD4.
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Introduction
There is considerable variability in the magnitude and rate
of CD4 T cell count recovery in Human immunodefi-
ciency virus type 1 (HIV-1)-infected individuals, receiving
antiretroviral therapy (ART). Most patients show a pro-
gressive rise in CD4 T cell counts after initiation of ART
[1,2], however, some patients fail to attain CD4 counts
that exceed 200 cells/μl, and thus remain profoundly
immune suppressed despite suppression of HIV-1 viral
replication. The frequency of suboptimal immunological
response to ART despite viral suppression varies between
7–20% [3-7] depending on the duration of ART and defi-
nition of SO-CD4 (see Table 1). There is limited data on
the frequency of suboptimal CD4 reconstitution despite
viral suppression (SO-CD4) in sub-Saharan Africa (SSA)
where most patients initiate ART at advanced stages of
HIV/AIDS [1,8,9] amidst a high background risk acute
infections. Moreover, there are conflicting reports about
the correlation of SO-CD4 with clinical morbidity and
susceptibility to opportunistic infections [4,5,10]. We
hypothesize that patients with SO-CD4 are at increased
risk of clinical events (death and/or recurrent or new
AIDS-defining illnesses). In this study, we determined the
frequency, predictors and clinical significance of SO-CD4
reconstitution as evidenced by of occurrence of acquired
immunodeficiency syndrome (AIDS)-related clinical
events (recurrent or new opportunistic infection and/or
death).
Patients and methods
Study site
The Infectious Diseases Institute (IDI) is a private-public
partnership institution that is a center of excellence in HIV
care, training, and research at Makerere University Medi-
cal School and Mulago Teaching Hospital in Kampala,
Uganda. Since 2004, the IDI clinic (IDC) has provided
free care to HIV positive patients, and by December, 2007,
IDC had enrolled 20,000 patients into HIV care, of whom
13,000 are in active follow-up and 4700 have initiated
ART according to WHO and Uganda Ministry of Health
guidelines. The clinic has 15 exam rooms and is staffed by
20 physicians, 30 nurses, and 10 counselors and patients
are reviewed monthly. The drugs are provided by the Glo-
bal Fund (a generic combined formulation of stavudine
[d4T, lamivudine [3TC], and nevirapine [NVP] or by the
US President's Emergency Plan for AIDS Relief (a com-
bined formulation of zidovudine [ZDV] and 3TC plus efa-
virenz [EFZ]/nevirapine [NVP]. Our research was
approved by the Uganda National Council of Science and
Technology.
Study subjects, procedures and measurements
From April 2004 to April 2005, 559 consecutive HIV-
infected patients initiating ART were enrolled into a pro-
spective observational research cohort if they attended the
clinic regularly (having attended at least 2 clinic visits in
the 6 months prior to ART initiation). Daily co-trimoxa-
zole prophylaxis was provided and patients allergic to co-
trimoxazole were given dapsone. Adherence to ART was
encouraged by at least 3 individual and group counseling
sessions. Patients are reviewed monthly by the general
clinic physicians that evaluated among others; adherence
to medication, toxicities and acute infections. Patients are
evaluated by the study physicians every 3 months or ear-
lier if they develop any illness. HIV RNA viral loads, com-
plete blood counts and CD4 lymphocyte counts are tested
at 6 monthly intervals.
Definitions of suboptimal CD4 reconstitution despite 
sustained viral suppression (SO-CD4)
In this study, we used (i) previously used definitions of
SO-CD4 in terms of the magnitude of the CD4 cell
increase [a CD4 count increase of < 50 CD4 cells/μl after
6 months of ART [3-6]; <100 cells/μl increase after 12
months [11]; and <200 cells/μl after 24 months; and (ii)
failure to achieve a CD4 cell count above a threshold of
200 cells/μl at 6, 12 and 24 months; the critical CD4
count below which patients remain highly susceptible to
opportunistic infections.
Statistical analysis
Patients were included in the analysis if they had attained
and sustained HIV-RNA viral load ≤ 400 copies per ml at
6, 12 and 24 months. The chi square test was used to com-
pare the baseline clinical characteristics of patients with
and without SO-CD4 and the level of significance was
0.05. Proportions of patients with SO-CD4 were calcu-
lated using the two criteria independently and with the
two criteria combined. The combination of the two crite-
ria was the intersection of patients with SO-CD4 on both
criteria I) and II). Logistic regression by stepwise model
selection was used to analyze predictors of SO-CD4. The
independent variables included age, sex, baseline CD4
cell counts, body mass index (BMI), baseline hemoglobin,
initial ART regimen, magnitude of CD4 increase in first 6
months and Hepatitis B surface Antigen sero-status. Vari-
ables were included in the multivariate model if they had
a p value ≤ 0.25 on bivariate analysis. The proportions of
clinical events were examined among patients with and
without SO-CD4. In addition, the cumulative risk of
development of AIDS-related clinical events was esti-
mated by Kaplan-Meier analysis. Patients were censored
on the occurrence of an AIDS-related clinical event (the
primary outcome) as required by the survival analysis
technique. Differences between the survival curves were
tested using the log-rank test.
Results
Baseline characteristics
Of 559 patients initiating ART, 386 (69%) were female,
with a median age of 38 yrs (IQR 33–44), and a median
CD4 count of 98 cells/μl (IQR 21–163). Half 283(51%)AIDS Research and Therapy 2008, 5:23 http://www.aidsrestherapy.com/content/5/1/23
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of the patients had severe immune suppression with CD4
counts below 100 cells/μl at initiation of ART. Majority of
patients, 414 (74%) started a d4T-based regimen
(D4T+3TC+NVP) and 145 (26%) a ZDV-based regimen
(ZDV+3TC+EFV). Baseline characteristics were compara-
ble among optimal and sub-optimal responders apart
from the baseline CD4 count that was significantly higher
among sub-optimal than optimal responders. Patients
Table 1: Published definitions of suboptimal CD4 reconstitution among patients with viral suppression
Author Cohort description Duration of 
follow up
Baseline CD4 
count
Median (IQR) 
cells/μl
ART regimen Definition of 
SO-CD4
and Frequency
Clinical events 
among suboptimal 
responders versus 
complete responders
Lawn [5] 596 ART-naïve patients 
at a community HIV 
clinic in Cape Town, 
South Africa
48 weeks 97 (50–153) 2 NRTIs + 1 
NNRTI
Increase < 50 
cells/μl at 12 
months
SO-CD4-7%
No data
Tuboi [6] 1914 ART naïve in HIV 
clinics in Africa, Latin 
America and Asia 
(ART-LINC)
6 months 137 (49–240) 2 NRTIs +1 
NNRTI
(57.3%)
2 NRTIs + PI 
(29%)
Increase < 50 
cells/μl at 6 
months
SO-CD4-19%
No data
Tan [7] Prospective 
observational cohort of 
404 ART naïve patients 
in an HIV clinic at the 
University of Alabama, 
Birmingham, US
9 months Mean = 214
(SD 260)
2 NRTIs +1 
NNRTI
(49%)
2 NRTIs + PI 
(40%)
Increase < 50 
cells/μl at 6 
months
SO-CD4-8.7%
Patients with discordant 
CD4 and virologic 
responses were 2.28 
times more likely to 
develop opportunistic 
infections/death aOR 
2.28(1.31–4.00)
Teixeira [10] 21 ART naïve patients 
attending an 
Immunology clinic at 2 
sites in the US 
(Ohio and San 
Francisco)
12 months 170 (90–276) No data Increase < 100 
cells/μl at 1 year
SO-CD4-57%
No data
Jevtovic [18] Retrospective study of 
446 patients at an HIV 
center in the Institute 
for Tropical diseases, 
Belgrade
52% ART naïve
33 months Mean 115 ± 95 2 NRTIs + PI 
(34%)
2 NRTIs+1 
NNRTI
(40%)
Absolute CD4 
count of < 400 
cells/μl at 2–3 
years
SO-CD4-39%
Clinical events were no 
higher among virologic 
only responders than 
complete CD4 & 
virologic responders
Florence [12] EuroSida study – 
Prospective cohort of 
8500 ART naïve 
patients in 63 hospitals 
of 20 European 
countries;
12 months 150 (80–228); 2 NRTIs + PI 
(86%)
2NRTIs 
+NNRTI 
(10.8%)
Increase < 50 
cells/μl at 6 
months
SO-CD4-29%
No data
Piketty [3] Prospective cohort of 
I62 ART experienced 
but PI -naive patients at 
an HIV clinic in France
12 months Mean 69 ± 5.0 2 NRTIs + PI Increase < 50 cells 
at 12 months
SO-CD4-10.5%
Higher Incidence of 
AIDS-defining events 
among virologic only 
responders (4/7) than 
complete responders (7/
92) [P = 0.07]
Grabar [4] Prospective cohort of 
2236 PI naïve patients 
from 68 hospitals in 
France
18 months 150(65–263) 2NRTIs +PI Increase < 50 
cells/μl at 6 
months
SO-CD4-17.3%
Patients with only good 
virologic responses 
were 3 times more 
likely to develop an 
AIDS-defining illness/
death than complete 
responders RR 3.38 
(2.28–5.02)
Kaufmann [13] Swiss cohort study – 
293 ART naïve patients
5 years 180 (60–311) 2NRTIs +PI 
(98%)
Absolute CD4 
count below 500 
cells/μl at 5 yrs
SO-CD4-35.8%
Higher incidence of 
CD4 category B events 
among incomplete 
responders (13.3%) than 
incomplete responders 
(9.6%) p > 0.05AIDS Research and Therapy 2008, 5:23 http://www.aidsrestherapy.com/content/5/1/23
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with a lower BMI at initiation of therapy were more likely
to have SO-CD4 after 12 months although the difference
was no longer significant after 24 months of ART. Simi-
larly, patients that initiated a ZDV-based regimen were
more likely to have SO-CD4 at 6 and 12 months although
the difference was no longer significant after 24 months of
ART (see Table 2). At 6 months, 93 (17%) were excluded
from analysis because; 6 did not have laboratory tests, 19
were lost to follow up and 68 were dead. The patients that
were lost to follow up had a median baseline CD4 count
of 144(11–189) cells/μl although their CD4 reconstitu-
tion could not be classified since they could not be
accessed for a second measurement. The majority (64%)
of the deaths among patients with viral suppression were
not HIV-related and the causes of death included among
others; drug-induced hepato-toxicity, lactic acidosis, road
traffic accidents and obstetric deaths (data not shown).
The median follow up was 22(IQR 3–22) months.
Suboptimal CD4 reconstitution
After 6, 12 and 24 months of ART, 380 (68%), 339 (61%)
and 309 (55%) had attained and sustained HIV-RNA viral
suppression. Of these, 78 (21%), 151 (45%) and 166
(54%) respectively had SO-CD4 using the CD4 increase
criteria (described in the methods section). Of the
patients with SO-CD4 at 6 months, 64/78 (82%) and 45/
78 (58%) still had SO-CD4 after 12 months and 24
months respectively. By the end of 2 years on ART the
overall median change in CD4 cell count and percentage
was 193(104–273) and 11.5% (IQR 8.6–14.6) respec-
tively though it was 77 [IQR 25–127] cells/μl and 7.2%
[IQR 4.1–9.6] respectively among patients with SO-CD4
(see figure 1).
Using the CD4 threshold criterion, 165/380 (43%), 143/
339(42%) and 58/309 (19%) had SO-CD4 at 6, 12 and
24 months of ART respectively. Of the patients with SO-
CD4 at 6 months, 112/165 (68%) and 46/165 (41%) still
Table 2: Baseline characteristics of patients with sustained viral suppression over 24 months in the Infectious Diseases. Institute 
research cohort
Duration of 
HAART
6 months (N = 380) 12 months (N = 339) 24 months (N = 309)
Variable CD4 
increase < 
50 cells/μl
CD4 
increase ≥ 
50 cells/μl
P value* CD4 
increase < 
100 cells/μl
CD4 
increase > 
100 cells/μl
P value CD4 
increase < 
200 cells/μl
CD4 
increase > 
200 cells/μl
P value
SO-CD4 78 (21%) 302 (79%) 151 (45%) 188 (55%) 166 (54%) 143 (46%)
Age (yrs), 
[median 
(IQR)]
38(33–44) 37(33–43) 38(33–45) 37(32–44) 37(32–44) 41(34–45)
≤ 35 30(38%) 126(42%) 0.60 53(35%) 84(45%) 0.14 58(35%) 69(48%) 0.02
Gender
Female 53(68%) 216(71%) 0.54 108(71%) 136(72%) 0.87 120(72%) 107(74%) 0.62
BMI increase 
[median 
(IQR)]
0.83 
(-0.4–2.0)
1.31 (0–2.56) 0.49 1.4(0.0–2.5) 2.3(0.7–3.9) <0.01 1.3(0–2.5) 2.8(0.7–4.6) 0.86
HAART 
regimen 
initiated
D4T-3TC-
EFZ/NVP
40(14%) 242(86%) 94(62%) 154(82%) 117(38%) 110(36%) 0.62
AZT-3TC-
EFZ/NVP
38(39%) 60(61%) <0.01 57(38%) 34(18%) <0.01 49(16%) 33(11%)
Baseline 
CD4 count 
[Median(IQR)]
123(84–186) 99(29–162) <0.01 122(78–189) 96(14–162) <0.01 119(77–176) 87(11–158) <0.01
Hepatitis 
BSAg *
(270 tests 
done)
Positive 8(31%) 18(69%) 0.17 10(7%) 11(6%) 0.93 10(6%) 11(8%) 0.24
Negative 59(20%) 233(80%) 114(75%) 145(77%) 131(79%) 102(71%)
* NOTE: The analysis was limited to only 270 patients that were tested for Hepatitis B surface antigen sero-statusAIDS Research and Therapy 2008, 5:23 http://www.aidsrestherapy.com/content/5/1/23
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had SO-CD4 at 12 and 24 months respectively. By 2 years
on ART the median change in CD4 cell count and percent-
age was 54 [IQR 22–99] cells/μl and 6.4% [IQR 3.5–8.1]
among patients with SO-CD4 based on threshold defini-
tion (see table 3).
With both criteria combined, 56/380 (15%), 129/339
(38%) and 3/309 (1%) had SO-CD4 after 6, 12 and 24
months of ART respectively. Of the patients with SO-CD4
at 6 months, 42/56 (75%) still had SO-CD4 after 12
months of therapy.
Predictors of SO-CD4
Patients with baseline CD4 counts of 50–199 cells/μl were
more likely to have SO-CD4 than those with baseline
CD4 counts of 0–49 cells/μl at 6 months [OR 2.5(1.1–
5.5) P = 0.03] and at 12 months [OR 2.9(1.6–5.4) P =
0.001]. In addition, patients who initiated zidovudine-
containing ART regimen were more likely to have SO-CD4
than patients on stavudine-containing ART at 6 months
[OR 4.5(2.4–8.3) P < 0.001] and at 12 months [3.6(2.0–
6.4) P < 0.001]. Other factors like age, sex, body mass
index and hemoglobin level were not significant predic-
tors of SO-CD4.
Clinical significance of suboptimal CD4 reconstitution
Overall, there were 22 clinical events/100 PYO (18–26)
among patients with sustained viral suppression. There
were no statistically significant differences in the clinical
events among patients with [19/100PYO (12–29)] and
without SO-CD4 (using the CD4 increase criteria) [23/
100PYO (19–28) p = 0.43] see Figure 2. The commonest
opportunistic infections (OIs) were oral candidiasis
(31%), bacterial pneumonia (22%), and tuberculosis
Scatter graphs showing the CD4 increases among patients on antiretroviral therapy with sustained viral suppression at 6, 12  and 24 months Figure 1
Scatter graphs showing the CD4 increases among patients on antiretroviral therapy with sustained viral sup-
pression at 6, 12 and 24 months.
Scatter graphs showing the CD4 increases among patients on antiretroviral therapy 
with sustained viral suppression at 6, 12 and 24 months
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(16%). Apart from oral candidiasis that occurred only at
CD4 counts below 100 cells/μl, there were no significant
differences in CD4 counts depending on the specific OIs.
Despite viral suppression, 14% and 30% of the OIs in the
first 6 months of therapy occurred among patients with
SO-CD4 using the CD4 increase and threshold criteria
respectively (see Table 3).
Discussion
In this population with good rates of viral suppression as
was previously reported [12], the frequency of SO-CD4,
using the CD4 increase criteria, was 21%, 45% and 54%
at 6,12 and 24 months respectively. Our findings are com-
parable to results from other developing countries (Africa,
Latin America and Asia) where 19% of patients had SO-
CD4 using a similar criteria of a CD4 increase of < 50
cells/μl after 6 months of ART [6]. Similarly, the frequency
of SO-CD4 at 6 and 12 months is comparable to what has
been reported in industrialized countries that used similar
criteria [4,11,13]. Overall, our results show similar pro-
files of CD4 reconstitution in both the developing and
industrialized countries despite the challenges with infra-
structure for care delivery in sub-Saharan Africa.
We found that patients with baseline CD4 counts of 50–
199 cells/μl were about 3 times more likely to have SO-
CD4 than those with baseline CD4 counts of 0–49 cells/
μl. Our results are similar to reports from South Africa
where patients in the lower CD4 stratum had a higher gra-
dient of CD4 increase [5]. This is contrary to previous
reports that advanced pre-treatment immunodeficiency is
associated with diminished capacity to restore quantita-
tive and functional CD4 T cell responses during antiretro-
viral therapy [14,15]. We attribute our results to the
peripheral expansion and/or redistribution of CD4 T cells
that is described in the initial phase of CD4 reconstitution
on ART [16]. Our results imply that the CD4 increase cri-
teria of SO-CD4 is not enough in a setting where patients
present to hospitals and HIV care units with untreated
advanced HIV disease [1,17]. In addition, we used a
threshold of 200 cells/μl below which patients were clas-
sified as SO-CD4 since this gives an indication of the gen-
eral susceptibility to opportunistic infections. Using the
CD4 threshold criteria, we found that 43%, 42% and 19%
had SO-CD4 at 6, 12 and 24 months respectively; thereby
remaining at risk of opportunistic infections.
Patients that initiated therapy with a zidovudine-contain-
ing regimen were 3.6 times more likely to develop SO-
CD4 than patients on a d4T-containing regimen and we
attribute this to the myelosuppressive effects of zidovu-
dine [18]. We interpret these results cautiously because
only 26% of our patients initiated a zidovudine-contain-
ing regimen and they were not randomized. However, evi-
dence in the US shows that use of a protease inhibitor
(PI)-based regimen is protective against poor immune
reconstitution [6,19] because PIs modulate activation of
peripheral blood CD4 T cells and decrease their suscepti-
bility to apoptosis [20]. Since the long term prognosis of
patients exhibiting discordant responses remains
unknown [3], we need to explore the use of the newer and
less toxic first line regimens [21] for patients at risk of SO-
CD4.
Age was not a significant predictor of SO-CD 4 in our
study and this is consistent with what was reported in a US
Table 3: Suboptimal CD4 reconstitution and clinical events among patients with sustained viral suppression in the infectious.
Duration of 
HAART
0–6 months (N = 380) 6–12 months (N = 339) 12–24 months (N = 309)
Variable Suboptimal 
response
Optimal 
response
P value Suboptimal 
response
Optimal 
response
P value Suboptimal 
response
Optimal 
response
P value
i)SO-CD4 
magnitude 
definition
78(21%) 302(79%) 151(45%) 188(55%) 166(54%) 143(46%)
OI events 11(14%) 77(25%) 0.04 14(9%) 9(5%) 0.13 8(5%) 4(3%) 0.40
ii)Threshold 
definition
165(43%) 215(57%) 143(42%) 196(58%) 58(18%) 309(82%)
OI events 49(30%) 66(31%) 0.90 11(8%) 12(6%) 0.66 1(0%) 11(8%) 0.70
iii) Definitions 
i & ii 
combined
56(15%) 324(85%) 129(38%) 213(62%) 3(1%) 306(99%)
OI events 8(10%) 80(26%) 0.12 9(6%) 14(7%) 0.36 2(1%) 11(8%) 0.70
Diseases Institute research cohort: we defined suboptimal CD4 reconstitution as i) CD4 count increase of either of a) less than 50 CD4 cells/μl at 
6 months [6] b) <100 cells/μl in the first year of therapy [10] and c) <200 cells/μl after 2 years of HAART; ii) CD4 T cell threshold of <200 cells/μl.AIDS Research and Therapy 2008, 5:23 http://www.aidsrestherapy.com/content/5/1/23
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cohort [22]. However, some previous studies showed that
age above 30 years was associated with SO-CD4 [5,11]
because it correlated with thymic involution yet preserved
thymic function is necessary for adequate CD4 T cell
recovery [11,23]. Similarly, hepatitis B co-infection did
not predict SO-CD4 as was recently reported that hepatitis
B co-infection had no impact on the response to ART
regarding viral suppression and immune recovery[24].
Majority of the patients with SO-CD4 after 6 months,
using either of the criteria, still had SO-CD4 at 12 months
despite sustained HIV-RNA viral suppression. Since
patients with SO-CD4 at 6 months are likely to maintain
the phenomenon, they may need evaluation of the recov-
ery of CD4 cell function, more so in Africa where there is
an increased background risk of opportunistic infections.
It is possible that the CD4 cells do not recover both in
absolute numbers and function because of the high levels
of T-cell activation in Africans due to frequent infections
by the various pathogens endemic in the region
[10,25,26].
It is also likely that these patients may require extended
periods of prophylaxis against opportunistic infections.
Our analysis was however limited to recovery of periph-
eral CD4 T cell counts and not CD4 T cell function. We
recommend studies to examine other markers of recovery
of immunological function among patients with SO-CD4.
We found that about a third of the opportunistic infec-
tions occurred among patients with SO-CD4 reconstitu-
tion as defined by either the CD4 increase or the threshold
criteria. Similar to what has been reported in other
cohorts, most of the AIDS-related events occurred in the
first 6 months [27-29] and the spectrum of opportunistic
infections was similar to what was found among patients
at Mulago hospital where most patients with advanced
HIV disease were hospitalized with severe bacterial pneu-
monias and tuberculosis [17]. More AIDS-related events
were recorded among patients without SO-CD4 and we
postulate that immune reconstitution inflammatory syn-
drome (IRIS) contributed to this difference [9]. However,
Kaplan-Meier analysis showed no statistically significant
Kaplan-Meier curve for AIDS-related clinical events for patients with and without suboptimal CD4 reconstitution despite viral  suppression (SO-CD4) at 6 months of antiretroviral therapy (Using the CD4 increase criteria) Figure 2
Kaplan-Meier curve for AIDS-related clinical events for patients with and without suboptimal CD4 reconstitu-
tion despite viral suppression (SO-CD4) at 6 months of antiretroviral therapy (Using the CD4 increase crite-
ria).
Kaplan-Meier curve for AIDS-related clinical events for patients with and without 
suboptimal CD4 reconstitution despite viral suppression (SO-CD4) after 6 months of 
antiretroviral therapy (Using the CD4 increase criteria) 
1.0
0
Probability 
of patients 
with CD4 
responses 
0.7
5
0.00
0.25
0.50 Log rank P=0.43
Optimal response 
SO-CD4
.5 1.5 012
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differences in the rates of AIDS-related clinical events
among patients with and without SO-CD4 in the setting
of HIV-RNA viral suppression. On the contrary, in indus-
trialized countries, patients with SO-CD4 (using similar
criteria) have previously been reported to have a higher
risk of developing an AIDS-related clinical events [4,30].
In the Swiss cohort, suboptimal responders had a 1.5 fold
higher incidence of opportunistic infections than the
complete CD4 responders [14]. However, we are cautious
to compare our results with the latter cohort because the
authors used a CD4 threshold below 500 cells/μl after 5
years of ART to define SO-CD4 at a frequency of 35.8%.
We need to consider SO-CD4 after longer periods of fol-
low up like has been done in the industrialized countries.
Our results add to the emphasis that viral load testing is
required for monitoring patients on ART in resource lim-
ited settings [31] especially those patients that present
with unsatisfactory CD4 reconstitution in order to guide
treatment decisions for this subgroup of patients.
The findings in this study are strengthened by the rela-
tively homogenous study population of ART-naive indi-
viduals receiving ART at a single facility using
standardized clinical protocols. Our patients used NNRTI-
based ART regimen that are used in most HIV care facili-
ties in Africa so our results can be generalized to most
patients in Africa however they are limited to patients
with sustained HIV-RNA viral suppression which, among
others, is the ultimate goal of ART. We need to design
studies of interventions for patients on ART with poor
immune reconstitution and minimize the time spent with
CD4 counts below the 200 cells/μl critical threshold. It is
important to note that adherence to ART and previous
exposure to ART were not considered to contribute to SO-
CD4 in our study since all patients were naïve to ART and
patients were included in the analysis only if they had
HIV-RNA viral load < 400 copies/ml which we used as a
proxy for good adherence.
Conclusion
The frequency of SO-CD4 is high in SSA and many of the
patients with SO-CD4 at 6 months maintain the phenom-
enon up to 2 years of therapy. However, the rates of AIDS-
related clinical events were no higher in those with SO-
CD4. We recommend studies of CD4 T-cell functional
recovery among patients with SO-CD4.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
DN conceived of the study, and participated in the design,
data analysis, interpretation of data, drafting and revising
the paper. AK participated in the study design and statisti-
cal analysis. FI participated in the statistical analysis. BC
participated in the acquisition of data, coordination of the
study and in revising the paper. MRK made substantial
contribution to the conception, design and coordination
of the study. PJE made substantial contribution study
design, statistical analysis and revision of the paper. All
authors read and approved the final manuscript.
Acknowledgements
The authors thank the Infectious Disease Institute research cohort team 
and all the patients in who participated in this study. We acknowledge Yuka 
Munabe and Robert Colebunders for their support in reviewing this paper.
References
1. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R,
Hanson D, Ochola D, Mugyenyi P, Mermin J, et al.: Assessment of a
pilot antiretroviral drug therapy programme in Uganda:
patients' response, survival, and drug resistance.  Lancet 2002,
360(9326):34-40.
2. Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard
B, Walsh J, Fisher M, Orkin C, et al.: Changes in outcome of per-
sons initiating highly active antiretroviral therapy at a CD4
count less than 50 Cells/mm3.  J Acquir Immune Defic Syndr 2008,
47(2):202-205.
3. Piketty C, Castiel P, Belec L, Batisse D, Si Mohamed A, Gilquin J,
Gonzalez-Canali G, Jayle D, Karmochkine M, Weiss L, et al.: Discrep-
ant responses to triple combination antiretroviral therapy in
advanced HIV disease.  Aids 1998, 12(7):745-750.
4. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Cos-
tagliola D, Weiss L: Clinical outcome of patients with HIV-1
infection according to immunologic and virologic response
after 6 months of highly active antiretroviral therapy.  Ann
Intern Med 2000, 133(6):401-410.
5. Lawn SD, Myer L, Bekker LG, Wood R: CD4 cell count recovery
among HIV-infected patients with very advanced immuno-
deficiency commencing antiretroviral treatment in sub-
Saharan Africa.  BMC Infect Dis 2006, 6:59.
6. Tuboi SH, Brinkhof MW, Egger M, Stone RA, Braitstein P, Nash D,
Sprinz E, Dabis F, Harrison LH, Schechter M: Discordant responses
to potent antiretroviral treatment in previously naive HIV-
1-infected adults initiating treatment in resource-con-
strained countries: the antiretroviral therapy in low-income
countries (ART-LINC) collaboration.  J Acquir Immune Defic
Syndr 2007, 45(1):52-59.
7. Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA,
Kempf MC: Clinical outcome of HIV-infected antiretroviral-
naive patients with discordant immunologic and virologic
responses to highly active antiretroviral therapy.  J Acquir
Immune Defic Syndr 2008, 47(5):553-558.
8. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R: Deter-
minants of mortality and nondeath losses from an antiretro-
viral treatment service in South Africa: implications for
program evaluation.  Clin Infect Dis 2006, 43(6):770-776.
9. Easterbrook PJ: HIV immune reconstitution syndrome in sub-
Saharan Africa.  Aids 2008, 22(5):643-645.
10. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA,
Lange JM, Hamann D, Prins M, Miedema F: Persistent immune
activation in HIV-1 infection is associated with progression
to AIDS.  Aids 2003, 17(13):1881-1888.
11. Teixeira L, Valdez H, McCune JM, Koup RA, Badley AD, Hellerstein
MK, Napolitano LA, Douek DC, Mbisa G, Deeks S, et al.: Poor CD4
T cell restoration after suppression of HIV-1 replication may
reflect lower thymic function.  Aids 2001, 15(14):1749-1756.
12. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala
F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira
AF, et al.: Predictors of long-term viral failure among ugandan
children and adults treated with antiretroviral therapy.  J
Acquir Immune Defic Syndr 2007, 46(2):187-193.
13. Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A,
Panos G, Katlama C, Vella S, Phillips A: Factors associated with a
reduced CD4 lymphocyte count response to HAART despite
full viral suppression in the EuroSIDA study.  HIV Med 2003,
4(3):255-262.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
AIDS Research and Therapy 2008, 5:23 http://www.aidsrestherapy.com/content/5/1/23
Page 9 of 9
(page number not for citation purposes)
14. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Ver-
nazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, et al.:
Characteristics, determinants, and clinical relevance of CD4
T cell recovery to <500 cells/microL in HIV type 1-infected
individuals receiving potent antiretroviral therapy.  Clin Infect
Dis 2005, 41(3):361-372.
15. Moore D, Montaner J: Total lymphocyte counts and ART in
resource-limited settings.  Lancet 2005, 366(9500):1831-1832.
16. Badolato R: Immunological nonresponse to highly active
antiretroviral therapy in HIV-infected subjects: is the bone
marrow impairment causing CD4 lymphopenia?  Clin Infect Dis
2008, 46(12):1911-1912.
17. Nakanjako D, Kyabayinze DJ, Mayanja-Kizza H, Katabira E, Kamya
MR: Eligibility for HIV/AIDS treatment among adults in a
medical emergency setting at an urban hospital in Uganda.
Afr Health Sci 2007, 7(3):124-128.
18. Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M: Treat-
ment initiation with zidovudine-containing potent antiretro-
viral therapy impairs CD4 cell count recovery but not clinical
efficacy.  Aids 2007, 21(8):939-946.
19. Jevtovic DJ, Salemovic D, Ranin J, Pesic I, Zerjav S, Djurkovic-Djakovic
O: The prevalence and risk of immune restoration disease in
HIV-infected patients treated with highly active antiretrovi-
ral therapy.  HIV Med 2005, 6(2):140-143.
20. Sloand EM, Kumar PN, Kim S, Chaudhuri A, Weichold FF, Young NS:
Human immunodeficiency virus type 1 protease inhibitor
modulates activation of peripheral blood CD4(+) T cells and
decreases their susceptibility to apoptosis in vitro and in
vivo.  Blood 1999, 94(3):1021-1027.
21. WHO: Antiretroviral therapy for HIV infection in adults and
adolescents in resource limited settings: Towards universal
access.  Recommendations for a public health approach 2006.
22. Patterson K, Napravnik S, Eron J, Keruly J, Moore R: Effects of age
and sex on immunological and virological responses to initial
highly active antiretroviral therapy.  HIV Med 2007,
8(6):406-410.
23. Aiuti F, Mezzaroma I: Failure to reconstitute CD4+ T-cells
despite suppression of HIV replication under HAART.  AIDS
Rev 2006, 8(2):88-97.
24. Omland LH, Weis N, Skinhoj P, Laursen A, Christensen PB, Nielsen
HI, Moller A, Engsig F, Sorensen HT, Obel N: Impact of hepatitis
B virus co-infection on response to highly active antiretrovi-
ral treatment and outcome in HIV-infected individuals: a
nationwide cohort study.  HIV Med 2008, 9(5):300-306.
25. Eggena MP, Barugahare B, Okello M, Mutyala S, Jones N, Ma Y, Kityo
C, Mugyenyi P, Cao H: T cell activation in HIV-seropositive
Ugandans: differential associations with viral load, CD4+ T
cell depletion, and coinfection.  J Infect Dis 2005, 191(5):694-701.
26. Borkow G, Weisman Z, Leng Q, Stein M, Kalinkovich A, Wolday D,
Bentwich Z: Helminths, human immunodeficiency virus and
tuberculosis.  Scand J Infect Dis 2001, 33(8):568-571.
27. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P,
Rickenbach M, Robins JM, Egger M: Long-term effectiveness of
potent antiretroviral therapy in preventing AIDS and death:
a prospective cohort study.  Lancet 2005, 366(9483):378-384.
28. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R: Early mortality
among adults accessing a community-based antiretroviral
service in South Africa: implications for programme design.
Aids 2005, 19(18):2141-2148.
29. Moore RD, Keruly JC: CD4+ cell count 6 years after com-
mencement of highly active antiretroviral therapy in persons
with sustained virologic suppression.  Clin Infect Dis 2007,
44(3):441-446.
30. Moore DM, Hogg RS, Yip B, Wood E, Tyndall M, Braitstein P, Mon-
taner JS: Discordant immunologic and virologic responses to
highly active antiretroviral therapy are associated with
increased mortality and poor adherence to therapy.  J Acquir
Immune Defic Syndr 2005, 40(3):288-293.
31. Smith DM, Schooley RT: Running with scissors: using antiretro-
viral therapy without monitoring viral load.  Clin Infect Dis 2008,
46(10):1598-1600.